Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Receives $280K to Support its Diagnostic Platform

NEW YORK (GenomeWeb News) – Response Biomedical said today that it has received C$283,756 (US$279,640) from the Canadian government to support its Ramp point-of-care platform.

The funding from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) will be used by Vancouver, British Columbia-based Response Biomedical for a project to improve the Ramp platform and increase the firm's ability to compete in the marketplace.

Response Biomedical did not elaborate on the project, saying only that the goal is to "improve the customer experience" with the platform.

The Ramp system consists of a reader and single-use disposable test cartridges. The Ramp Reader and Ramp 200 reader are portable scanning fluorescence quantitative analysis platforms for near-patient testing.

Clinical tests for the Ramp system are currently available for the early detection of heart attack and congestive hear failure. In the non-clinical arena, Ramp tests exists for the environmental detection of West Nile Virus, as well biodefense applications such as the on-site detection of anthrax, smallpox, ricin, and botulinum toxin.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.